Literature DB >> 21108338

A matched case-control study of hepatitis B virus mutations in the preS and core promoter regions associated independently with hepatocellular carcinoma.

Shijian Liu1, Jiaxin Xie, Jianhua Yin, Hongwei Zhang, Qi Zhang, Rui Pu, Chengzhong Li, Wu Ni, Hongyang Wang, Guangwen Cao.   

Abstract

This study aimed to determine hepatitis B virus (HBV) mutations associated independently with the risk of hepatocellular carcinoma (HCC), as adjusted with other mutations in the preS and core promoter regions of HBV genotypes B and C. One hundred and forty HBV-infected patients with HCC and 280 HBV-infected patients without HCC who had intact data of HBV genotyping and DNA sequencing in both regions were involved in this age-, sex-matched case-control study. Univariate and two-step stepwise multivariate regression analyses were performed to determine factors associated with the risk of HCC. Of 39 mutations evaluated, 23 in genotype C and 6 in genotype B were associated with an increased risk of HCC in the univariate analysis. Multivariate analyses established that genotype C (adjusted odds ratio [AOR] = 3.3; 95% confidence interval [CI] = 1.1-9.8), viral load (≥10(4) copies/ml) (AOR = 2.4; 95% CI = 1.0-5.8), A2962G (AOR = 18.7; 95% CI = 7.5-46.7), preS2 start codon mutation (AOR = 12.5; 95% CI = 3.4-45.5), C105T (AOR = 0.1; 95% CI = 0.0-0.2), T1753V (AOR = 3.1; 95% CI = 1.1-9.2), and A1762T/G1764A (AOR = 2.9; 95% CI = 1.1-7.3) were associated independently with HCC, adjusted for factors including mutations in both regions. By using an estimating haplotype frequencies program, it was found that a haplotypic carriage with 105C and 2962G was significantly more frequent in the patients with HCC than in those without HCC and the frequency of haplotype 2962G-preS2 start codon wildtype-105C-1762T/1764A was 47.9% in the patients with HCC and 4.3% in those without HCC. Conclusively, A2962G and T105C are novel factors associated independently with HCC. Further prospective studies are needed to confirm the role of these mutations in the development of HCC.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21108338     DOI: 10.1002/jmv.21829

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  22 in total

Review 1.  Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.

Authors:  Li-Ping Chen; Jun Zhao; Yan Du; Yi-Fang Han; Tong Su; Hong-Wei Zhang; Guang-Wen Cao
Journal:  World J Virol       Date:  2012-12-12

Review 2.  Genetic variation of hepatitis B virus and its significance for pathogenesis.

Authors:  Zhen-Hua Zhang; Chun-Chen Wu; Xin-Wen Chen; Xu Li; Jun Li; Meng-Ji Lu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 3.  Overview of hepatitis B viral replication and genetic variability.

Authors:  Shuping Tong; Peter Revill
Journal:  J Hepatol       Date:  2016-04       Impact factor: 25.083

Review 4.  Cancer Evolution-Development: experience of hepatitis B virus-induced hepatocarcinogenesis.

Authors:  W B Liu; J F Wu; Y Du; G W Cao
Journal:  Curr Oncol       Date:  2016-02-18       Impact factor: 3.677

5.  Association between HBV Pre-S mutations and the intracellular HBV DNAs in HBsAg-positive hepatocellular carcinoma in China.

Authors:  Hui Wang; Ai-Hua Wang; Olav A Gressner; Meng Fang; Xing Gu; Qiang Ji; Shu-Qun Cheng; Feng Shen; Chun-Fang Gao
Journal:  Clin Exp Med       Date:  2014-12-11       Impact factor: 3.984

6.  Predictive power of hepatitis B 1762T/1764A mutations in plasma for hepatocellular carcinoma risk in Qidong, China.

Authors:  Alvaro Muñoz; Jian Guo Chen; Patricia A Egner; Melinda L Marshall; Jamie L Johnson; Michael F Schneider; Jian Hua Lu; Yuan Rong Zhu; Jin-Bing Wang; Tao Yang Chen; Thomas W Kensler; John D Groopman
Journal:  Carcinogenesis       Date:  2011-04-07       Impact factor: 4.944

7.  Synergistic effects of A1896, T1653 and T1762/A1764 mutations in genotype c2 hepatitis B virus on development of hepatocellular carcinoma.

Authors:  H Lyu; D Lee; Y-H Chung; J A Kim; J-H Lee; Y-J Jin; W Park; P Mathews; E Jaffee; L Zheng; E Yu; Y J Lee
Journal:  J Viral Hepat       Date:  2012-08-16       Impact factor: 3.728

8.  Challenges of incorporating gene expression data to predict HCC prognosis in the age of systems biology.

Authors:  Yan Du; Guang-Wen Cao
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

9.  Prediction and prophylaxis of hepatocellular carcinoma occurrence and postoperative recurrence in chronic hepatitis B virus-infected subjects.

Authors:  Yan Du; Xue Han; Yi-Bo Ding; Jian-Hua Yin; Guang-Wen Cao
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

10.  Quantitative evaluation of hepatitis B virus mutations and hepatocellular carcinoma risk: a meta-analysis of prospective studies.

Authors:  Yang Yang; Jiang-Wei Sun; Long-Gang Zhao; Freddie Bray; Yong-Bing Xiang
Journal:  Chin J Cancer Res       Date:  2015-10       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.